Aptar Pharma Pays Pharmaxis US $5m to Acquire Orbital Technology
4th Aug 22
Release Date: 04/08/2022 5:12pm
- Drug delivery leader Aptar Pharma exercises option for a worldwide license to the “Orbital” technology for $US2.5m and a subsequent option for an outright purchase of the technology for a further US$2.5 million.
- Aptar Pharma’s decision supported by the potential for safe and convenient administration of high dose treatments to the lungs
- Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler
Categories: News and Media